BioStem Technologies ( (BSEM) ) has released its Q1 earnings. Here is a breakdown of the information BioStem Technologies presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioStem Technologies, Inc., a MedTech company specializing in the development and commercialization of placental-derived biologics, has reported its preliminary financial results for the first quarter of 2025, showcasing significant growth and strategic advancements in the wound care sector.
In the first quarter of 2025, BioStem Technologies achieved a remarkable 73% increase in net revenue, reaching $72.5 million compared to the same period in 2024. This growth is attributed to the successful launch and rapid adoption of Vendaje AC®, a key product in their wound care portfolio, and expanded commercial efforts.
The company reported a gross profit of $71.7 million, representing 99% of net revenue, an improvement from the previous year’s 95%. Operating expenses rose to $66.4 million, driven by increased sales and marketing efforts. Despite this, BioStem maintained a positive GAAP net income of $4.5 million, marking its fifth consecutive quarter of profitability.
BioStem continues to strengthen its position in the chronic wound care market with strategic initiatives, including new clinical trials for its BioREtain® Amnion Chorion and Vendaje® products. The company is also expanding its intellectual property portfolio, with a total of 55 patents issued and 52 pending.
Looking ahead, BioStem remains focused on growth and innovation in regenerative medicine. The company is actively pursuing an uplisting to Nasdaq, which is expected to enhance its market presence and shareholder value. Management expresses confidence in its strategic direction and the continued support of its stakeholders.